Warfarina y aspérrima en pacientes con patología cardiaca en el hospital obrero n° 2 de la caja nacional de salud / Warfarin and aspérrima in patients with cardiac pathology in the worker hospital n ° 2 of the national health fund

Las drogas con efecto anticoagulante y antiagregante plaquetario, son un componente fundamental del manejo profiláctico de pacientes con patología cardiaca. Su efectividad se ha demostrado claramente en la prevención secundaria de accidentes cerebrovasculares. El objetivo del trabajo fue describir y comparar la eficacia profiláctica y complicaciones del tratamiento con warfarina y aspirina en pacientes con patología cardiaca que asistieron a consulta externa de cardiología del Hospital Obrero N°2 de la Caja Nacional de Salud de enero del 2001 a enero del 2003, el universo fue de 350 pacientes, y la muestra de 152, los cuales cumplían los criterios de inclusión (indicación de anticoagulacion y/o antiagregacion, inicio de tratamiento en el periodo de estudio, controles periódicos clínicos y laboratoriales de INR/TP y otros exámenes de gabinete de apoyo diagnostico. Los resultados obtenidos son significativos: 40 casos (26,31%) recibieron profilaxis con warfarina con dosis variables e individuales; 62 casos (40,78%) con 100 mgrs de acido acetilsalicílico y 50 casos (32,89%) con terapia combinada (warfarina y aspirina). 24 casos (15,78%) presentaron complicaciones por sobreanticoagulacion o subanticoagulacion; siendo por terapia combinada (warfarina y aspirina) 12 casos (50%); warfarina 6 casos (25%) y aspirina 6 casos (25%). Las complicaciones mas frecuentes fueron: enfermedad cerebrovascular isquémica, hemorragia digestiva alta. La terapia profiláctica con anticuoagulantes y/o antiagregantes fue eficaz en la mayor parte de los casos, las complicaciones se presentaron especialmente en el grupo que recibió profiaxis combinada, siendo las más frecuentes las de tipo isquémico y hemorrágico.

Drugs with anticoagulant and platelet antiagregant effect are a fundamental component of the prophylactic management for patients with heart pathology. Their effectiveness has been shown clearly in secondary prevention of brain ischemic stroke. The objective of this work it was to describe and compare the prophylaxis effectiveness and complications of warfarina vs aspirin treatment in patients with heart pathology that attended to cardiology' external consultation at HO N° 2 of the CNS from January 2001 to january 2003. The universe was conformed by 350 patients, the sample with 152 patients than fulfilled inclusión criteria (indication of anticoagulation and antiagregation, treatment beginnig at same time of study's periodo, periodic clinical and laboratorial controls INR/TP and other diagnostic support tests. The results obtained were: 40 casos (26.31%) recevied prophylaxis with warfarina with variable and singular dose, 62 cases (40.78%) with 100 mgr of aspirin and 50 cases (32.89 %) with both. 24 cases presented complications due to overanticoagulatión or subanticoagulation, 12 cases with combineed therapy , warfarina 6 cases y aspirin 6 cases. The most often complications were: CVI, high digestive haemorrage. Anticoagulant prophilactic theraphy was eficace in most cases. Most frequent complications were in combined prophylactic groups, ischemic and haemorragic type.

Study on pilot manufacture of aspirine microgelules

Announcement of some initial results of making and investigating some particularizes of aspirin microfollicle. Percentage of asprin between theory and reality has remarkable change (+16.57 to -1.37). In generally, the microcapsules sample have low rate of Asp/EC, the aspirin microencapsulated rate is high and vice versa. Parameters of asparin percentage, rate of Asp/EC influence on asparin microencapsulated rate. Asparin capsule with EC box can be made with relatively high microencapsulated rate productivity. Aspirin capsule can last liberation of pharmaceutical material and give long-lasting effect in systems

Curative effects observation of treatment with Plaix and Aspirine for patients with progressive cerebral infarction / 临床神经病学杂志

Objective Investigate the efficacy of Plaix and Aspirine on treating the patients with progressive cerebral infarction.Methods 92 patients with progressive cerebral infarction were randomly divided into unite therapy group(n=46) and control groups(n=46).Two groups were taken the conventional therapy.In the patients of unite therapy group,oral Plaix 75 mg and Aspirine 150 mg per day,control group oral Aspirine 150 mg per day.Clinical neural deficiency score(NDS) was given before and 30 d after treatment for comparison and measur blood solidifying function and Heraorheological indexes.Results Total effective rate in the unite therapy group(93%)was significant higher than that in the control group(74%)(P